Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02824666 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242
A Phase 1 study, sponsored by Braeburn Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT02824666 is a Phase 1 study that has completed, run by Braeburn Pharmaceuticals. The registered enrollment target is 7 participants.
The verdict
NCT02824666, a Phase 1 study, has completed, sponsored by Braeburn Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study involves evaluating the occupancy of ATI-9242 at steady state at three different dose levels on D2 receptors in the brain using \[18F\] Fallypride PET in up to three cohorts of subjects.
Interventions
- DRUG ATI-9242
- RADIATION [18F]Fallypride Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-06-20 |
| Est. Completion | 2016-11-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02824666
The ClinicalTrials.gov registry entry for NCT02824666 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Braeburn Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ATI-9242 is the first listed.
NCT02824666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02824666 about?
NCT02824666 is a clinical study titled "Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242". This study involves evaluating the occupancy of ATI-9242 at steady state at three different dose levels on D2 receptors in the brain using \[18F\] Fallypride PET in up to three cohorts of subjects.
What is the current status of trial NCT02824666?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2016-06-20. Estimated completion is 2016-11-08.
What interventions are being tested in trial NCT02824666?
The interventions under investigation include: ATI-9242 (DRUG), [18F]Fallypride Imaging (RADIATION).
Who is sponsoring clinical trial NCT02824666?
This trial is sponsored by Braeburn Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.